GlycoGenesys, Inc., (NASDAQ: GLGS), a biotechnology company focused on carbohydrate-based drug development, provided a corporate update on its cancer clinical trial programs for GCS-100, its pipeline expansion strategy and the expected timelines for its drug development programs. Today the Company announced: -- The addition of a site to its initiated Phase I/II multiple myeloma trial;
-- Plans for its Phase I/II clinical trial in chronic lymphocytic leukemia (CLL);
-- A more detailed clinical development plan and timelines for GCS-100 in solid tumors and bloodborne cancers;
-- Efforts to establish a long-term funding relationship in 2005 to help fund its clinical trial programs and pipeline expansion
UPDATE ON 2005 GCS-100 CANCER PROGRAM
The Company’s clinical program positions it to pursue approval in two indications for unmet medical needs in cancer (multiple myeloma and CLL) and starts the international regulatory process for GCS-100. This is in addition to the Company’s continuing solid tumor program. The Company may also choose to apply for Fast Track designation in the U.S. for one or both bloodborne indications in the future.
